Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells

SIMPLE SUMMARY: Sorafenib (Nexavar@) is the only currently approved anti-cancer drug for patients with advanced hepatocellular carcinoma (HCC). However, despite the development of strategies combining sorafenib with other cytotoxic chemotherapeutic agents to overcome sorafenib resistance, clinical t...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Yusun, Han, Yeonju, Kim, Dongwoo, Cho, Sua, Kim, WonJin, Hwang, Hyemin, Lee, Hye Won, Han, Dai Hoon, Kim, Kyung Sik, Yun, Mijin, Lee, Misu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909034/
https://www.ncbi.nlm.nih.gov/pubmed/35267513
http://dx.doi.org/10.3390/cancers14051205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909034/
https://www.ncbi.nlm.nih.gov/pubmed/35267513
http://dx.doi.org/10.3390/cancers14051205

Ejemplares similares